Company intelligence / Profile preview
Tvardi Therapeutics
Sugar Land, Texas, United Statestvarditherapeutics.com ↗
- Ownership
- Public · TVRD
- Development stage
- Other
01
Overview
Tvardi's lead candidate TTI-101 showed promising results in Phase 1 trials with advanced solid tumors, demonstrating dose-linear pharmacokinetics and decreased levels of phosphotyrosine STAT3 within paired tumor biopsies. No dose-limiting toxicities or treatment-related adverse events greater than grade 3 were observed. The company is currently conducting Phase 2 trials for IPF and HCC with data readouts expected in the second half of 2025 and first half of 2026 respectively.
- Therapeutic areas
- OncologyPulmonologyRare DiseasesImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $11.5M
- Total revenue
- $0
- Enterprise value
- $-4.1M
Beyond the preview
Go deeper on Tvardi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tvardi Therapeutics.